secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001323885-24-000013
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q4 revenue $106.5M (+21%), full-year adj EBITDA positive $19.4M; guides 2024 rev ~$459-466M
--------------------------------------------------------------------------------

- Q4 2023 revenue $106.5M (+21% YoY); full-year revenue $399.2M (+20.8%).
- Full-year 2023 net loss improved $16M to $30.4M; adjusted EBITDA turned positive to $19.4M from -$2.2M.
- Full-year diluted net loss per share $0.66 vs $1.02 in 2022; adjusted loss per share $0.75 vs $1.02.
- 2024 revenue guidance $459-$466M (15-17% growth); adjusted EBITDA $26-$29M (34-49% increase).
- Over one million patients treated life to date; management cites broad-based expansion and momentum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388524000013/0001323885-24-000013-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388524000013/atrc-20240215.htm
  HTML page:      https://secwatch.observer/filing/0001323885-24-000013

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer